

**NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017**

Tuesday, April 18

TIME	SESSION #	SESSION	COURSE DIRECTOR(S)	NOTES	CREDITS
7:30am – 5:15pm	220	Kidney Transplant: Principles and Practice	Krista Lentine, MD, PhD	●	
7:30am – 5:30pm	620	Critical Care Nephrology	Laurie Benton, PA-C, FNKF	●	
7:30am – 4:30pm	221	Successful Dialysis: Who, What, Where, When and How	Daniel Weiner, MD, MS, FNKF Jeffrey Perl, MD, SM, FRCPC	●	
7:30am – 12:30pm	223	Kidney Stones	David Goldfarb, MD, FNKF	●◆	
7:30am – 12:30pm	224	Point of Care Ultrasound for the Nephrologist	Kenar Jhaveri, MD, FNKF	●	
8:00am – 5:30pm	222	Supportive Care in Nephrology: Teaching the Clinician, Treating the Patient	Jane Schell, MD Alvin Moss, MD Michael Germain, MD	●◆	
8:00am – 6:00pm	225	Glomerular Diseases: Updates on Pathogenesis and Treatment	Fernando Fervenza, MD, PhD, FNKF Gerald Appel, MD, FNKF	●	
1:00pm – 6:30pm	226	Vascular Access: A Crash Course on Practical Essentials <i>Held in conjunction with the American Society of Diagnostic and Interventional Nephrology</i>	Tushar Vachharajani, MD, FASN, FACP Loay Salman, MD	●	
6:30pm – 8:00pm	100	Fellows Networking Reception/Career Choices in Nephrology	Sylvia E. Rosas, MD, MSCE, FNKF		

Wednesday, April 19

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	800	Calcimimetics for Secondary Hyperparathyroidism: Something Old, Something New <i>Supported by an educational donation provided by Amgen</i>	Chair: Myles Wolf, MD	◆	1.5
		Introduction and Program Overview	Myles Wolf, MD		
		Pathophysiology of Secondary Hyperparathyroidism: Emerging Risk Factors and Impact on Clinical Outcomes	Csaba Kovesdy, MD		
		Optimizing Biochemical Control in SHPT: Effect of Calcimimetic-Based Regimens on Biochemical and Clinical Outcomes	James Wetmore, MD		
8:00am – 9:30am	260	MACRA-Economics: Nephrology in the New Health System	Chair: Daniel Weiner, MD, MS, FNKF		1.5
		The Merit-Based Incentive Payment System: What Every Provider Needs to Know	Bob Doherty		
		Alternative Payments Models in Nephrology (ESCOs and Other Possibilities)	Jeffrey Berns, MD, FNKF		
		Quality Metrics in Kidney Disease: I Know It When I See It, But...	Daniel Weiner, MD, MS, FNKF		
8:00am – 9:30am	261	Therapeutic Dilemmas in Nephritic Syndrome	Chair: Jai Radhakrishnan, MD	◆	1.5
		Immunosuppression in IgAN: STOP or Start?	Pietro Canetta, MD		
		Treatment-Resistant Lupus Nephritis: What Now?	Hanni Menn-Josephy, MD		
		Enough is Enough: When Can I Stop Maintenance Therapy for ANCA Vasculitis in the Post-RAVE Era?	Patrick Nachman, MD, FASN		
8:00am – 9:30am	262	Immunologic Risks: Advances in Immunosuppression and Rejection Management	Chairs: Krista Lentine, MD, PhD & Dorry Segev, MD, PhD	◆	1.5
		Immunosuppression Minimization Protocols: Risks and Benefits	Robert Gaston, MD		
		Approach to the Highly Sensitized Candidate	Didier Mandelbrot, MD		
		Treatment of Antibody-Mediated Rejection	Peter Nickerson, MD		
9:30am – 10:00am		Break			

NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017

10:00am – 11:30am	263	Non-Immunologic Risks in Kidney Transplant	Chairs: Matthew Cooper, MD, and Robert Gaston, MD	1.5
		Managing Cardiovascular Risk Before and After Transplant	Krista Lentine, MD, PhD	
		Understanding the Risks of Frailty in the Elderly Candidate	Peter Reese, MD	
		Realizing HOPE: Organ Transplantation from HIV-Positive Donors	Dorry Segev, MD, PhD	
10:00am – 11:30am	264	DEBATE: Is it Time to SPRINT to Lower Blood Pressure Targets in CKD?	Chairs: Tara Chang, MD, MS & Dena Rifkin, MD, MS, FNKF	◆ 1.5
		SPRINT – What Did This Landmark Trial Show?	Tara Chang, MD, MS	
		NO – We Should Not Lower Blood Pressure Targets in CKD	Raymond Townsend, MD	
		YES – We Should Lower Blood Pressure Targets in CKD	Joachim Ix, MD, MAS, FASN	
11:30am – 12:00pm		Break		
12:00pm – 2:00pm	801	Management and Hyperphosphatemia in ESRD: Old Challenges, New Solutions	Chair: Daniel Coyne, MD	◆ 1.5
		<i>Supported by an educational grant from Fresenius Medical Care</i>		
		Introductory presentation on disease state	Daniel Coyne, MD	
		Pathophysiology, Risk Factors, and Consequences of Hyperphosphatemia in CKD and ESRD	Csaba Kovesdy, MD	
		Treatment Options for Hyperphosphatemia in ESRD: Making the Best Choices for Optimal Individual Outcomes	Jessica Kendrick, MD	
12:00pm – 2:00pm	230	Workshop: Renal Pathology: A Case-Based Approach to Rare Kidney Diseases	Chair: Laurence Beck, Jr., MD, PhD, FNKF	● 2.0
		Cases	Gearoid McMahon, MD Helmut Rennke, MD	
12:00pm – 2:00pm	231	Workshop: Hemato-Nephrology: A Case-Based Discussion	Chair: Rimda Wanchoo, MD	● 2.0
		Hematological Malignancies and Renal Disease	Anushree Shirali, MD	
		Electrolyte Disorders Seen in Liquid Malignancies	Claude Bassil, MD	
		Renal Disease Associated with Hematopoietic Stem Cell Transplants	Rimda Wanchoo, MD	
12:00pm – 2:00pm	232	Workshop: PD: Expect the Unexpected	Chair: Jeffrey Perl, MD, SM, FRCPC	● 2.0
		PD for This Patient? Really?	Joanne Bargman, MD, FRCPC	
		Where Did My Fluid Go?	Jeffrey Perl, MD, SM, FRCPC	
		Peritonitis: The Weird but Not So Wonderful	Beth Piraino, MD, FNKF	
12:00pm – 2:00pm	233	Workshop: My Patient's Lytes Are Out	Chairs: Matthew Abramowitz, MD, MS, and Kalani Raphael, MD, MS	●◆ 2.0
		Chronic Hyponatremia: Cognition, Falls, and Fractures	Joseph Verbalis, MD	
		Approach to the Patient with Hypomagnesemia	Stanley Goldfarb, MD	
		Post-Transplant Electrolyte Disorders	Lee Hamm, MD	
12:00pm – 2:00pm	234	Workshop: Professional Development Seminar	Chairs: Sylvia E. Rosas, MD, MSCE, FNKF	●
		<i>Held in conjunction with Women in Nephrology (WIN)</i>	Ellie Kelepouris, MD, FAHA	
		Am I on the Right Track: Research, Clinic, or Education?	Katherine Tuttle, MD	
		Essentials of Leadership	Richard Glasscock, MD	
		Preparing for an Interview	Wendy Brown, MD, MPH, FNKF	
		Contract and Salary Negotiations: Academia and Private Practice	Ellie Kelepouris, MD, FAHA	
		Career Challenges: Work-Life Balance and Time Management	Holly Kramer, MD, MPH	
12:00pm – 2:00pm	235	Workshop: Clinical Challenges with Vascular Access Care	Chair: Michele Mokrzycki, MD	● 2.0
		AVF Maturation - Are We There Yet?	Lynn Poole, FNP, CNN, FNKF	

NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017

		"The Last Option"	Tushar Vachharajani, MD, FASN, FACP		
		CRBSI – Collecting the Right Sample	Michele Mokrzycki, MD		
2:00pm – 2:15pm		Break			
2:15pm – 4:00pm	265	Shaul G. Massry Distinguished Lecture: The Ailing Kidneys Under Pressure – and It's Not Just Systolic	Raymond Townsend, MD		1.5
		NKF Presidential Address	Michael Choi, MD, FNKF		
		Keynote Presentation: Kidney Exchange: Recent History and Future Opportunities	Alvin Roth, PhD		
4:00pm – 4:15pm		Break			
4:15pm – 5:45pm	266	Clinical Conundrums in Nephrotic Syndrome	Chair: Laurence Beck, Jr., MD, PhD, FNKF	◆	1.5
		Thick or Thin? Anticoagulation in the Nephrotic Syndrome	Patrick Nachman, MD, FASN		
		Can We Ever Rule Out Malignancy in Membranous Nephropathy?	Richard Glasscock, MD		
		FSGS: To Treat or Not to Treat (with Immunosuppression)?	Fernando Fervenza, MD, PhD, FNKF		
4:15pm – 5:45pm	267	Oral Anticoagulant Use for Stroke Prevention in Patients Undergoing Maintenance Dialysis: A KDOQI Debate	Chair: Holly Kramer, MD	◆	1.5
		Evidence Presentation	Vinod Bansal, MD		
		Anticoagulant Use - Pro	Peter McCullough, MD		
		Anticoagulant Use - Con	Manish Sood, MD		
4:15pm – 5:45pm	268	Caring for Older Patients with Multi-Morbidity	Chairs: Michael Germain, MD, and Jane Schell, MD		1.5
		Finding Out What Matters Most: Role of Prognosis and Patient Values to Guide Treatment Decisions	Robert Cohen, MD		
		Care Coordination Across Transitions for Patients with Multi-Morbidity	Debra Hain, PhD, APRN, ANP, GNP		
		Whose Job Is It Anyway? Strategies to Guide Advance Care Planning in Kidney Patients	Mark Unruh, MD		
6:00pm – 7:30pm		Opening Ceremonies and Reception in the Exhibit Hall – Visit Posters/Exhibits			
7:30pm – 9:30pm	802	New Paradigms in the Treatment of Hyperkalemia <i>Supported by an educational grant from ZS Pharma</i>	Chair: Ravi Thadhani, MD	◆	1.5
		Pathophysiology and Risk Factors of Chronic Hyperkalemia	Jay Wish, MD		
		Chronic Hyperkalemia in CKD and ESRD: Outcomes and Traditional Therapies	Ravi Thadhani, MD		
		Novel Treatments for Chronic Hyperkalemia: Is it Time for a New Therapeutic Paradigm?	Mikhail Kosiborod, MD		

Thursday, April 20

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:45am	803	Strategies to Improve Patient Outcomes in CKD-MBD Management <i>Supported by an educational grant from Sanofi Aventis U.S.</i>	Chair: Hartmut Malluche, MD	◆	1.5
		Pathogenesis and Clinical Manifestations of CKD-MBD	Rajnish Mehrotra, MD, MS		
		Evaluation and Monitoring for CKD-MBD	Hartmut Malluche, MD		
		Management Strategies for CKD-MBD	Csaba Kovesdy, MD		
6:00am – 7:45am	804	Volume First: Reassessing the Importance of Dry Weight Assessment and Optimal Fluid Management in Hemodialysis	Chair: Daniel Weiner, MD, MS, FNKF	◆	1.5

NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017

<i>Supported by an educational grant from Fresenius Medical Care</i>				
		Introduction	Daniel Weiner, MD, MS, FNKF	
		Optimizing Volume Management in Hemodialysis: The Importance of a “Volume First” Approach	Jennifer Flythe, MD	
		Dry Weight Assessment in Hemodialysis: The Cornerstone of Volume Management	Rajiv Agarwal, MD	
7:00am – 8:30am		Continental Breakfast in the Exhibit Hall – Visit Posters/Exhibits		
8:30am – 10:00am	269	Oy VAD: Heart Failure and Kidney Disease 2017	Chair: Daniel Weiner, MD, MS, FNKF	1.5
		Ventricular Assist Devices: A Primer	Susan Joseph, MD	
		CKD, Dialysis and VADS	Jamie Dwyer, MD Helen Smiltneek, RN	
8:30am – 10:00am	270	Home Hemodialysis Challenges and Solutions	Chairs: Christopher Chan, MD, and Joel Glickman, MD	1.5
		Would Patients Leave Home? Factors Associated with Discontinuation of Home Hemodialysis	Rebecca Seshasai, MD	
		Growing a Home Dialysis Program	Joel Glickman, MD Deborah Evans, MSW	
8:30am – 10:00am	271	New Treatment Options for Anemia Management: The Role of Iron and Biosimilars in Nephrology	Chair: Jay Wish, MD	1.5
		New Iron-Based Treatment Options for Iron Deficiency Anemia	Daniel Coyne, MD	
		The Biosimilar Approval and Extrapolation Process – The Curious Case of Epoetin	Jay Wish, MD	
		Epoetin Alpha, Beta or Theta? The Emerging Role of Biosimilar Epoetins in Anemia Treatment	Steven Fishbane, MD	
8:30am – 10:00am	292	Trainee Poster Tour	Chair: Sylvia Rosas, MD	
		Expert faculty will provide trainees with a tour of specially selected posters that highlight the newest advances in nephrology.	Dan Negoianu, MD TBD	
10:00am – 10:30am		Break		
10:30am – 12:00pm	272	Walking a Tightrope: Oral Anticoagulation and Kidney Disease	Chair: Wolfgang Winkelmayr, MD, ScD	1.5
		Safety and Efficacy of Warfarin in ESRD	Manish Sood, MD	
		Anticoagulant Induced AKI: Clinical and Pathological Considerations	Sergey Brodsky, MD	
		Role of Novel Oral Anticoagulants in CKD	Wolfgang Winkelmayr, MD, ScD	
10:30am – 12:00pm	273	All About Conduits	Chair: Louise Moist, MD	1.5
		Choosing Wisely – Right Choice at the Right Time	Louise Moist, MD	
		Cardiovascular Mortality and Early AVF Creation in Elderly	Timmy Lee, MD, MSPH	
		Cardiac Rhythm Device and Central Vein Preservation	Loay Salman, MD	
10:30am – 12:00pm	274	Palliative Care Primer for the Nephrology Team	Chairs: Michael Germain, MD	1.5
		What, When and How of Palliative Care for Kidney Patients	Jennifer Scherer, MD	
		Conservative Care: Who’s Doing It and How Can I?	Jane Schell, MD	
		Delivering Palliative Care in Dialysis: It’s a Team Effort	Dan Lam, MD	
12:00pm – 2:00pm		Break in the Exhibit Hall – Lunch Served 12:00pm – 1:30pm		

NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017

2:00pm – 3:30pm	275	Controversies in Renal Replacement Therapy for Acute Kidney Injury	Chairs: Paul Palevsky, MD, FNKF, and Sean Bagshaw, MD, MSc, FRCPC	◆	1.5
		Timing of Renal Replacement Therapy Initiation in AKI	Sean Bagshaw, MD, MSc, FRCPC		
		My Approach to the Prescription of RRT for AKI	Paul Palevsky, MD, FNKF		
		The Perils of Survival: How Can We Improve Outcomes After an Episode of AKI?	Ron Wald, MD, MPH		
2:00pm – 3:30pm	276	Optimizing Outcomes in Home Hemodialysis	Chairs: Joel Glickman, MD and Christopher Chan, MD		1.5
		The Biologic Basis of Improved Outcomes in More Frequent Hemodialysis	Christopher Chan, MD		
		What is STD Kt/V and is it a Valid measurement of Adequate Dialysis Dose?	Matthew Rivara, MD		
		Should Assessment of More Frequent Hemodialysis Adequacy be a Composite Measurement?	Joanne Bargman, MD, FRCPC		
3:30pm – 4:00pm		Break			
4:00pm – 5:30pm	277	iNephrology: The Next Frontier	Chairs: Delphine Tuot, MDCM, MAS, FNKF and Jerry Yee, MD, FNKF		1.5
		Health Information Technology for CKD/ESRD Patient Self-Management	Stephanie Ong, RPh, ACPR, BScPhm, MSc		
		Does mHealth Reduce or Exacerbate Disparities in Kidney Care?	Clarissa Diamantidis, MD, MHS, FNKF		
		Tele-Nephrology to Enhance Nephrology's Reach	Eric Wallace, MD		
4:00pm – 5:30pm	278	What's New in Diabetic Kidney Disease	Chairs: Vivek Bhalla, MD, and Katherine Tuttle, MD, FNKF	◆	1.5
		Update on the Pathophysiology of Diabetic Kidney Disease	Vivek Bhalla, MD		
		Out, Out, Damned K! Novel Drugs to Manage Hyperkalemia	Jaime Dwyer, MD		
		Beyond RAAS Inhibitors: Novel Drugs for Diabetic Kidney Disease	Katherine Tuttle, MD, FNKF		
4:00pm – 5:30pm		Late Breaking Research			1.5
		Cluster-Randomized Trial of Device to Prevent Catheter-Related Bloodstream Infection in Hemodialysis Patients	Steven Brunelli, MD		
		Treatment Of Active Lupus Nephritis With Voclosporin: 48 Week Data From The Aura-LV Study	Samir Parikh		
		The Effect Of Topically Applied Vonapanitase On Fistula Outcomes: Results Of The Patency-1 Trial	Anthony Bleyer		
5:30pm – 7:00pm		Networking Reception in the Exhibit Hall – Visit Posters/Exhibits			
7:00pm – 9:00pm	806	Management of Hepatitis C in Late-Stage CKD Patients: Who, How, and When to Treat?	Chair: David Roth, MD	◆	1.5
		<i>Supported by an educational grant from Merck & Co., Inc.</i>			
		The Challenge of Hepatitis-C Management in Late-Stage CKD Patients: Cause and Complication	Meghan Sise, MD		
		Management of the ESRD Patient with HCV Infection	David Roth, MD		
		Emerging Treatment Approaches for Hepatitis C in Kidney Transplantation	Roy Bloom, MD		

Friday, April 21

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
7:00am – 8:45am	805	The Challenges of Treating Iron Deficiency Anemia in Patients with Non-Dialysis Chronic Kidney Disease	Chair: Steven Fishbane, MD	◆	1.5
		<i>Supported by an educational grant from Keryx Biopharmaceuticals, Inc.</i>			
		Physiology of Iron Metabolism	Orlando Gutierrez, MD		
		Pathophysiology of Iron Deficiency Anemia	Jay Wish, MD		

NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017

		Conventional and Novel Strategies for Treating Iron Deficiency Anemia in Patients with ND-CKD	Steven Fishbane, MD		
7:00am – 8:45am	807	Reducing Risk of Hyperkalemia in Chronic Kidney Disease: New Insights, New Treatments <i>Supported by an educational grant from Relypsa, Inc.</i>	Chair: Csaba Kovessy, MD	◆	1.5
		The Underlying Risk of Hyperkalemia in CKD: A Potential Silent Killer	Charles Wingo, MD		
		Diagnosis and Evaluation of Emergent and Non-Emergent Hyperkalemia	Biff Palmer, MD		
		Novel Treatment Options for the Management of Hyperkalemia	Csaba Kovessy, MD		
7:00am – 10:00am		Break in the Exhibit Hall (Breakfast Served 7:00am – 8:30am) – Visit Posters/Exhibits			
8:45am – 9:45am	279	We Don't Have to Fail at Acute Renal Failure: A Multidisciplinary Approach to Quality Improvement	Paul Palevsky, MD, FNKF	◆	1.0
9:45am – 10:00am		Break			
10:00am – 11:30am	280	Blood Pressure Management Version 2.0	Chairs: Tara Chang, MD, MS, and Joachim Ix, MD, MAS, FASN	◆	1.5
		Measuring Blood Pressure Outside of Clinic: When, Where, and How?	Christopher McFadden, MD		
		Rebuff the Cuff: Novel Ways to Measure Blood Pressure	Vivek Bhalla, MD		
		Caveat Emptor: Potential Pitfalls with New Technology	Timothy Plante, MD, MHS		
10:00am – 11:30am	281	Debate: Fluid First	Chair: Holly Kramer, MD, MPH, FNKF		1.5
		Assessing Volume Status in Dialysis	Christopher McIntyre, MD		
		Debate: Ultrafiltration Rate Metric for HD			
		Pro	Daniel Weiner, MD, MS, FNKF		
		Con	Jenny Flythe, MD, MPH		
11:30am – 12:00pm		Break			
12:00pm – 1:30pm	236	Lunch Workshop: Cardiology Calls a Consult: Cardiovascular Procedures and the Role of the Nephrologist	Chairs: Jai Radhakrishnan, MD and Susan Joseph, MD	●	1.5
		I Have a Patient with Heart Failure and Worsening Renal Function	Jai Radhakrishnan, MD		
		I Have a Patient with AKI Now s/p TAVR and Has AKI	Kenar Jhaveri, MD, FNKF		
		I have a Patient in the Cardiac ICU on ECMO and Dialysis	Susan Joseph, MD		
12:00pm – 1:30pm	237	Lunch Workshop: Breaking Bad: Overcoming Barriers for Nephrology Education	Chairs: Bernard Jaar, MD, FNKF, and Sandeep Soman, MD, FNKF	●	1.5
		Patient Education: Barriers and Solutions	Varun Agrawal, MD		
		Tools to Help PCP's Optimize CKD Care	Khaled Abdel-Kader, MD, FNKF		
		Advances in Nephrology/Resident Training Tools	John Sperati, MD, MHS, FNKF		
12:00pm – 1:30pm	238	Lunch Workshop: Critical Care Medicine for the Nephrologist	Chairs: Ron Wald, MD, MPH, and F. Perry Wilson, MD	●◆	1.5
		What's New in the ICU? A Review of this Past Year's Literature in Critical Care Medicine	Ron Wald, MD, MPH		
		Fluids in the ICU: How Much is Enough? Which one Should I Use?	Dan Negoianu, MD		
		Management of Hepatic Failure: What the Nephrologist Needs to Know	Sean Bagshaw, MD, MSc, FRCPC		
1:30pm – 2:00pm		Break			
2:00pm – 3:30pm	808	Battling Resistance in Glomerular Disease: A New Look at Treatment Options <i>Supported by an educational grant from Mallinckrodt Pharmaceuticals.</i>	Chairs: Nelson Leung, MD, and Jai Radhakrishnan, MD	◆	1.5
		Mechanisms and Pathways: Newest Understandings	Nelson Leung, MD		

**NKF 2017 Spring Clinical Meetings
Physician Program
As of March 22, 2017**

		Distinctions, Controversies, and Challenges in Glomerular Disease	Jeffrey Kopp, MD	
		Battling Resistance: What's the Evidence?	Jai Radhakrishnan, MD	
2:00pm – 3:30pm	282	The CDC CKD Surveillance System – Surveillance of CKD in the United States	Chairs: Rajiv Saran, MD and Neil Powe, MD, MPH, MBA	1.5
		Tracking Trends in CKD Prevalence in the CDC CKD Surveillance System	Neil Powe, MD, MPH, MBA	
		National and State-Level Awareness of CKD in the United States	Delphine Tuot, MDCM, MAS, FNKF	
		Monitoring Acute Kidney Injury in a CKD Surveillance System	Michael Heung, MD	
2:00pm – 3:30pm	283	Acid-Base and Electrolyte Cases	Chair: Kalani Raphael, MD, MS	◆ 1.5
		Acid-Base Cases	Lee Hamm, MD	
		Electrolyte Cases	Alan Yu, MD	
3:30pm – 4:00pm		Break		
4:00pm – 5:30pm	284	Acute Kidney Injury in Hospitalized Patients	Chairs: Thomas Nolin, PharmD, PhD, and Mark Perazella, MD	◆ 1.5
		Quality Improvement in the Care of Patients with AKI: Alerts, Notifications and Bundles	F. Perry Wilson, MD	
		Drug-Induced AKI	Mark Perazella, MD	
		Drug Dosing in Patients Receiving RRT for AKI	Thomas Nolin, PharmD, PhD	
4:00pm – 5:30pm	285	Balancing Bicarbonate in CKD	Chairs: Lee Hamm, MD, and Kalani Raphael, MD, MS	1.5
		Bicarbonate: Good for the Kidneys...	Kalani Raphael, MD, MS	
		Bicarbonate: ...Bad for the Heart?	Mirela Dobre, MD	
		The Base Rx: Diet or Pills and What Do We Target?	Matthew Abramowitz, MD, MS	
4:00pm – 5:30pm	286	The Dialysis Outcomes Practice Pattern Study (DOPPS) Program: Study Growth Reveals New Insights	Chair: Ronald Pisoni, PhD, MS	1.5
		Key Lessons from the First 20 Years of DOPPS	Ronald Pisoni, PhD, MS	
		The Latest in U.S. Hemodialysis Practices: Insights from the DOPPS Practice Monitor	Steven Brunelli, MD	
		PDOPPS: PD Practices and Outcomes that Stand Out in U.S. vs. Internationally	Jeffrey Perl, MD, SM, FRCPC	
		CKDopps: Optimizing Advanced CKD Practices and the Transition to Dialysis	Rachel Perlman, MD	

Saturday, April 22

TIME	SESSION #	SESSION	FACULTY	NOTES	CREDITS
6:00am – 7:30am		Team Kidney 5K Fun Run!		●	
8:30am – 10:00am	287	Overcoming Nature and Nurture: Reducing Disparities in Kidney Disease	Chairs: Clarissa Diamantidis, MD, MHS, FNKF, and Neil Powe, MD, MPH, MBA		1.5
		ApoL1 and Beyond: Genetic Contributions to Kidney Disease	Barry Freedman, MD		
		Setting Up for Kidney Failure: Socioeconomic Contributors Across the Lifespan	Neil Powe, MD, MPH, MBA		
		Reducing Disparities Through Health Policy: Think National, Act Local	Justin List, MD, MAR, MSc		
8:30am – 10:00am	288	Home Dialysis: Starting Strong and Achieving Long Term Success	Chairs: Isaac Teitelbaum, MD, and Joel Glickman, MD		1.5
		Home HD vs. PD: Enemies or Allies?	Joel Glickman, MD		
		Technique Failure in PD: Who's to Blame?	Isaac Teitelbaum, MD		
		Urgent Start PD: Trials and Tribulations	Jeffrey Perl, MD, SM, FRCPC		

NKF 2017 Spring Clinical Meetings

Physician Program

As of March 22, 2017

10:00am – 10:30am		Break		
10:30am – 12:00pm	289	Ask the Experts: Case-Based Discussion of Paraproteinemic Kidney Disease	Chairs: Nelson Leung, MD, and Kenar Jhaveri, MD, FNKF	1.5
		Diagnosis of Paraproteinemic Diseases: A Conundrum	Nelson Leung, MD	
		Glomerular Diseases Associated with Paraproteinemias	Albert Lam, MD	
		Nephrotoxicities of Novel Agents Used to Treat Myeloma	Rimda Wanchoo, MD	
10:30am – 12:00pm	290	Gut Microbiome Derived Metabolites: Worthy of Targeted Intervention in CKD?	Chairs: Jonathan Himmelfarb, MD, and Meredith Marinaro, MS, RD	◆ 1.5
		The Gut Microbiome in CKD: A Source of Uremic Toxicity	Dominic Raj, MD	
		TMAO: A Biomarker of Atherosclerosis in CKD	Jason Stubbs, MD	
		Utility of Pre-, Pro-, and Synbiotics to Modulate the Microbiome in CKD	Tammy Sirich, MD	
12:00pm		Meeting Adjourns		

● Separate Registration and/or Fee Required

◆ ABIM MOC Points Offered